Here’s what you should know:
1. Takeda could sell Shire’s eye-disease treatment, Xiidra, and its hypoparathyroidism treatment, Natpara.
2. Analysts believe the two drugs could return up to $5 billion if sold.
3. The acquisition is expected to close in March 2019 if approved.
More articles on supply chain:
Mackinaw Surgery Center recognized by SPH Analytics — 3 insights
5 must-read articles for GI physicians this week: Sept. 6-12
How one ASC reduced infection rates while adding total joint procedures
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.